Great question — these two medications work in very different ways, so it's worth understanding the distinction.
Vyndaqel (tafamidis meglumine) is a TTR *stabilizer*. It works by keeping the TTR protein from breaking apart and forming the amyloid deposits that cause damage. It's taken as a daily oral capsule, which is Show Full Answer
Great question — these two medications work in very different ways, so it's worth understanding the distinction.
Vyndaqel (tafamidis meglumine) is a TTR *stabilizer*. It works by keeping the TTR protein from breaking apart and forming the amyloid deposits that cause damage. It's taken as a daily oral capsule, which is convenient.
Amvuttra (vutrisiran) is a *silencer* — it works earlier in the process by blocking the body from producing the abnormal TTR protein in the first place. It's given as an injection under the skin once every three months by a healthcare professional. In terms of what they're approved for:
- Vyndaqel is approved for heart disease caused by wild-type or hereditary ATTR amyloidosis
- Amvuttra is approved for both nerve damage (polyneuropathy) and cardiomyopathy in ATTR amyloidosis
It's not unusual for treatment availability to vary by country. The UK's NHS approval process is separate from the FDA in the US, which can mean some treatments take longer to become available or may not yet be covered.
Talking to a specialist amyloidosis centre in the UK — such as those in London or Oxford — could be worthwhile, as they may have access to options or clinical trials beyond what's routinely offered.
AI-generated responses are not a substitute for medical advice. These services are not intended to
diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.
8 Amyloidosis Treatments and Their Side Effects
October 5
Join
Your Privacy Choices
